{"product_id":"biolegend-652411","title":"Biolegend, 652411, Brilliant Violet 421™ anti-mouse Ki-67 Antibody, 50μg","description":"\u003cp\u003eThe nuclear protein Ki-67 was first identified by the monoclonal antibody Ki-67, which was generated by immunizing mice with nuclei of the L428 Hodgkin lymphoma cell line. Ki-67 protein plays an essential role in ribosomal RNA transcription and cell proliferation. Expression of Ki-67 occurs during G1, S, G2, and M phase, while in G0 phase the Ki-67 protein is not detectable. Ki-67 is strongly expressed in proliferating cells and has been reported as a prognostic marker in various tumors.\u003cbr\u003e\n50μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: E. coli expressed partial mouse Ki-67 recombinant protein, 1816-2163 aa.\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.\u003cbr\u003e\nConcentration: 0.2 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: ICFC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by our Ki-67 staining protocol below. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450\/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.\u003cbr\u003e\nExcitation Laser: Violet Laser (405 nm)\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Medina-Reyes EI, et al. 2015. Environ Res. 136:424. PubMed Guillaumond F, et al. 2015. PNAS. 112:2473. PubMed Sharma SK, et al. 2015. J Immunol. 194:5529. PubMed Rodero MP, et al. 2014. J. Invest. Dermatol. 7:1991-7. PubMed\u003cbr\u003e\nProduct Citations: Lee K, et al. 2023. JCI Insight. 8:. PubMed Broadfield LA, et al. 2022. Mol Metab. 61:101498. PubMed Li W, et al. 2023. Bioact Mater. 22:34. PubMed Weng S, et al. 2022. Front Immunol. 13:1025931. PubMed Lin YH 2023. Immunity. 56(1):207-223.e8. PubMed Fiege JK, et al. 2021. Cell Host Microbe. 29:1815. PubMed Piper CJM, et al. 2020. Cell Reports. 29(7):1878-1892.e7.. PubMed Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed Montes de Oca R, et al. 2021. Mol Cancer Ther. 20:1941. PubMed Wang G, et al. 2021. Nat Commun. 12:5733. PubMed Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed Zhang H, et al. 2020. Cancer Cell. 37(1):37-54.e9.. PubMed Dai B, et al. 2022. Theranostics. 12:7603. PubMed Prasad M, et al. 2021. Front Immunol. 12:644483. PubMed Ma X, et al. 2021. Cell Metabolism. 33(5):1001-1012.e5. PubMed Ma X et al. 2019. Cell Metab. 30(1):143-156 . PubMed MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed Yu X, et al. 2019. Nat Commun. 10:574. PubMed Yao Y, et al. 2018. Cell. 175:1634. PubMed Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed Lehrke MJ, et al. 2021. Elife. 10:. PubMed Rustenhoven J, et al. 2021. Cell. 184(4):1000-1016.e27. PubMed Li N, et al. 2022. Nat Commun. 13:7281. PubMed Fedele C, et al. 2021. J Exp Med. 218: . PubMed\u003cbr\u003e\nRRID: AB_2562663 (BioLegend Cat. No. 652411)\u003cbr\u003e\nStructure: 325 kD protein containing a forkhead-associated domain (FHA) and 13 tandem repeats\u003cbr\u003e\nDistribution: Nucleus and chromosome\u003cbr\u003e\nFunction: Required for cell cycle progression and proliferation\u003cbr\u003e\nInteraction: Interacts with KIF15; binds to MKI67IP through FHA domain\u003cbr\u003e\nBiology Area: Cell Biology, Cell Cycle\/DNA Replication, Transcription Factors\u003cbr\u003e\nMolecular Family: Nuclear Markers\u003cbr\u003e\nAntigen References: 1. Starborg M, et al. 1996. J. Cell. Sci. 109:143. 2. Byeon IJ, et al. 2005. Nat. Struct. Mol. Biol. 12:987. 3. Yerushalmi R, et al. 2010. Lancet. Oncol. 11:174. 4. Beltrami AP, et al. 2001. N. Engl. J. Med. 344:1750. 5. Sachsenberg N, et al. 1998. J. Exp. Med. 187:1295. 6. Nagy Z, et al. 1997. Acta. Neuropathol. 93:294.\u003cbr\u003e\nGene ID: 17345\u003cbr\u003e\nUniProt: View information about Ki-67 on UniProt.org\u003cbr\u003e\nClone: 16A8\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: KIA, proliferation-related Ki-67 antigen\u003cbr\u003e\nIsotype: Rat IgG2a, κ\u003cbr\u003e\nQ: What is the F\/P ratio range of our BV421™ format antibody reagents?\u003cbr\u003e\nA: It is lot-specific. On average it ranges between 2-4.\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46864358080681,"sku":"652411","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/biolegend-652411","provider":"Iright","version":"1.0","type":"link"}